See more : Kanseki Co., Ltd. (9903.T) Income Statement Analysis – Financial Results
Complete financial analysis of 180 Life Sciences Corp. (ATNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 180 Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- INTOSOL Holdings PLC (INTO.L) Income Statement Analysis – Financial Results
- Metal Sky Star Acquisition Corporation (MSSA) Income Statement Analysis – Financial Results
- PT Modern Internasional Tbk (MDRN.JK) Income Statement Analysis – Financial Results
- Maven Income and Growth VCT 4 PLC (MAV4.L) Income Statement Analysis – Financial Results
- Q Technology Group Limited (QTG.AX) Income Statement Analysis – Financial Results
180 Life Sciences Corp. (ATNF)
About 180 Life Sciences Corp.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 0.00 | 0.00 |
| Gross Profit | -105.68K | -109.00K | -116.30K | -125.33K | -72.24K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.78M | 2.43M | 3.95M | 2.29M | 2.04M | 1.07M | 0.00 |
| General & Administrative | 10.69M | 15.47M | 11.69M | 3.32M | 5.89M | 7.67M | 343.88K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 38.83K | 12.96M | 0.00 | 0.00 |
| SG&A | 10.69M | 15.47M | 11.69M | 3.36M | 18.85M | 7.67M | 343.88K |
| Other Expenses | 0.00 | 246.34B | 770.60K | 264.74K | 250.40K | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Cost & Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Interest Income | 0.00 | 26.67K | 186.21K | 1.09M | 181.41K | 12.24K | 663.02K |
| Interest Expense | 44.83 | 26.67K | 186.21K | 1.09M | 185.14K | 0.00 | 0.00 |
| Depreciation & Amortization | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 23.08K | 52.52K |
| EBITDA | -22.13M | -17.79M | -20.05M | -5.52M | -20.79M | -8.72M | -343.88K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -17.90M | -15.64M | -5.65M | -20.86M | -8.74M | -343.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.81M | -21.77M | -4.71M | -5.26M | -4.54M | -5.75M | 663.02K |
| Income Before Tax | -22.28M | -39.67M | -20.35M | -10.90M | -25.40M | -14.50M | 319.13K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.35M | 942.75K | 23.20K | 20.43K | 9.50K | -1.00 | 195.37K |
| Net Income | -19.94M | -38.73M | -20.32M | -12.01M | -25.39M | -14.50M | 123.76K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -52.60 | -387.26 | -247.86 | -255.46 | -875.66 | -1.45K | 12.38 |
| EPS Diluted | -52.59 | -387.18 | -246.32 | -251.32 | -874.45 | -1.45K | 12.38 |
| Weighted Avg Shares Out | 379.00K | 100.00K | 82.00K | 47.00K | 29.00K | 10.00K | 10.00K |
| Weighted Avg Shares Out (Dil) | 379.09K | 100.02K | 82.51K | 47.77K | 29.04K | 10.00K | 10.00K |
Elicit Plant nomme Pam Marrone et Johan de Saegher à son Conseil d’administration
MOULINS-SUR-TARDOIRE, France--(BUSINESS WIRE)--Elicit Plant, une agri-biotech spécialisée dans la résistance des plantes au stress hydrique qui développe une plateforme technologique à base de phytostérols, annonce aujourd’hui la nomination à son Conseil d’administration de Dr. Pam Marrone en tant que Présidente...
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”) in connection to its merger with 180 Life...
Using News to Find Penny Stocks to Buy: 3 Tips
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
3 Essential Strategies for Penny Stocks Trading in 2023
Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The 7 Most Sold-Off Stocks of 2022
With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the...
180 Life Sciences (ATNF) Stock: 1-For-20 Reverse Split Goes Into Effect
A 1-for-20 reverse split of 180 Life Sciences (ATNF) stock has gone into effect. These are the details.
Why 180 Life Sciences Shares Are Plunging Today
180 Life Sciences Corp (NASDAQ: ATNF) received a written response from the U.K.'s regulatory agency and U.S. FDA related to questions submitted in a Type C meeting request for anti-TNF treatment, adalimumab, to treat early-stage Dupuytren's disease. Dupuytren's disease.
180 Life Sciences (ATNF) Stock: Why The Price Jumped Up Today
The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 11% pre-market today. This is why it happened.
180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022
PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
Source: https://incomestatements.info
Category: Stock Reports